![](/img/cover-not-exists.png)
Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
Guy, Holly, Walder, Lydia, Fisher, MarkLanguage:
english
Journal:
PharmacoEconomics
DOI:
10.1007/s40273-019-00803-7
Date:
May, 2019
File:
PDF, 494 KB
english, 2019